Renal Cancer Clinical Trial
Official title:
Which is Better to Assess Postoperative Complications in Patients Undergoing Laparoscopic Partial Nephrectomy?: Clavien-Dindo Classification Versus Comprehensive Complication Index.
This study aims to compare the strength of the classical Clavien-Dindo classification system (CDC), which is a Likert scale analysis versus the comprehensive complication index (CCI), a new quantitative evaluation system, in patients undergoing laparoscopic partial nephrectomy (LPN).
Prospectively collected data of sixty-two patients undergoing LPN with postoperative complications from November 2009 to August 2020 were evaluated retrospectively. Postoperative complications were classified according to the CDCs and calculated using the CCI calculator (https://www.assessurgery.com) quantitatively. Major complications were determined as ≥ grade 3 complications according to the CDC. The complexity of the renal mass was defined according to the RENAL nephrometry score. The cut-off value for CCI was analyzed by the ROC analysis technique. The significance level was taken as p<0.05. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
| Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03203473 -
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
|
Phase 2 | |
| Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
| Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
| Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
| Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
| Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
| Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
| Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 |